Michael Ferguson, MD, MS

Michael Ferguson, MD, MS

Assistant Professor, Pediatrics & Medicine

Phone: 317-944-2143
Email: micjferg@iu.edu
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202



Pediatric Hematology Oncology  & Clinical Pharmacology (Medicine)

Areas of Interest

Neurofibromatosis Type I & II, Sarcomas, Phase I trials


My research interests include novel agents for the treatment of relapsed or refractory tumors including those encountered in Neurofibromatosis type I & II


1999 BS, University of Notre Dame
2004 MS, Cellular & Integrative Physiology, Indiana University-Purdue University, Indianapolis, IN
2007 MD, Indiana University School of Medicine
2010 Residency, Indiana University School of Medicine
2013 Fellow- Hematology/ Oncology, Indiana University School of Medicine
2014 Fellow- Clinical Pharmacology, Indiana University School of Medicine
2014 MS, Clinical Research, Indiana University School of Medicine

Honors & Awards

  • 2003: Rodney A. Rhoades Masters Award for Academic Excellence, Indiana University School of Medicine
  • 2006: Gold Humanism Honor Society, Indiana University School of Medicine
  • 2009, 2011: Red Shoes Award - Family recognition for outstanding clinical care, Indiana University School of Medicine
  • 2011-2014: Morris Green Scholars Program, Indiana University School of Medicine
  • 2012-2014: Brater Scholar for Personalized Medicine, Indiana University School of Medicine
  • 2012-2015 St. Baldrick’s Foundation Fellow
  • 2014: Member of Professional Advisory Board, Neurofibromatosis Midwest


Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
317-944-2143 phone
317-944-3107 fax

Research & Grants

The goal of the my research is to either discover or utilize available or novel drug inhibitors to treat various relapsed or refractory tumors including those encountered in both Neurofibromatosis type I (NF1) and type 2 (NF2).  My ultimate goals are to evaluate the effects of numerous combinations of inhibitors of numerous cancer promoting pathways implicated in tumorigenesis of all sarcomas, plexiform neurofibromas, schwannomas, and malignant peripheral nerve sheath tumors (MPNST).  As we have no FDA approved agents to treat these various tumors, there is a need for novel drug development for targeted pathways causing these tumors and malignancies.  Additionally, due to my education in clinical pharmacology, I have been active in analyzing pharmacokinetic, pharmacodynamics, and pharmacogenetic parameters on patients taking one or multiple agents.  Thus my research goal is not only to identify molecular targeted therapy to use for treating these tumors, but also to evaluate the metabolism, disposition, and drug-drug interactions related to treatment with one or more molecular-targeted agents.   With generous funding from the St. Baldrick's Foundation, I wish to understand various inhibitors’ metabolism, disposition, and potential for interactions in order to optimize drug therapy and induce greater reduction in refractory and/or NF-related tumor burden while limiting those with adverse effects to combinatorial therapy. 

NIH-LRP Pediatric – Extramural July 1, 2013 – June 30, 2015 Determining Efficacy of Combinatorial Therapy in Treatment of Plexiform Neurofibromas Role: Principal Investigator Goals: To determine the efficacy of numerous small molecular inhibitors of the Ras and PI3K pathways utilized in combinations to treat plexiform neurofibromas and determine through drug interaction studies the appropriate dosing regimens to limit toxicity Mentor: D. Wade Clapp, MD

St. Baldrick’s Foundation Fellow Award July 1, 2012 – June 30, 2015 Experimental Therapeutics in the Treatment of Plexiform Neurofibromas Role: Principal Investigator/Fellow Goals: Evaluation of existing experimental compounds along with a novel inhibitor of Rac1 in a preclinical murine model of plexiform neurofibromas


Ferguson MJ, Hingorani P, Gupta AA. Emerging Molecular-Targeted Therapies in Early-Phase Clinical Trials and Preclinical Models. What’s New and Improved in the Care of Children with Rhabdomyosarcoma? ASCO 2013. Educational Book 420-424

Egbelakin A, Ferguson MJ, Macgill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric Blood Cancer. 2011 Mar;56(3): 361-7

Kevin M. Sheridan, Michael J. Ferguson, Matthew R. Distasi, Frank A. Witzmann, Michael C. Dalsing, Steven J Miller, Joseph L. Unthank. Impact of genetic background and aging on mesenteric collateral growth capacity in Fischer 344, Brown Norway, and Fischer 344-Brown Norway hybrid rats. American Journal of Physiology-Heart and Circulatory Physiology. 2007 Dec; 293(3): H3498-3505.

McKee EE, Ferguson M, Bentley AT, Marks, TA. Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones. Antimicrobial Agents and Chemotherapy. 50: June 2006